Nanoparticles as contrast agents for the diagnosis of Alzheimer's disease: a systematic review

Marina Ulanova; Anne Poljak; Wei Wen; Andre Bongers; Lucy Gloag; Justin Gooding; Richard Tilley; Perminder Sachdev; Nady Braidy

doi:10.2217/nnm-2019-0316

Nanoparticles as contrast agents for the diagnosis of Alzheimer's disease: a systematic review

Nanomedicine (Lond). 2020 Mar;15(7):725-743. doi: 10.2217/nnm-2019-0316. Epub 2020 Mar 6.

Authors

Marina Ulanova¹, Anne Poljak^{1

2

3}, Wei Wen¹, Andre Bongers^{2

4}, Lucy Gloag^{5

6}, Justin Gooding^{5

6

7}, Richard Tilley^{2

5

6}, Perminder Sachdev^{1

8}, Nady Braidy¹

Affiliations

¹ Centre for Healthy Brain Ageing, School of Psychiatry, The University of New South Wales, Sydney, NSW, 2052, Australia.
² Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, NSW, 2052, Australia.
³ School of Medical Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.
⁴ Biological Resources Imaging Laboratory, Mark Wainwright Analytical Centre, The University of New South Wales, Sydney, NSW, 2052, Australia.
⁵ School of Chemistry, The University of New South Wales, Sydney, NSW, 2052, Australia.
⁶ Australian Centre for NanoMedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.
⁷ ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, The University of New South Wales, Sydney, NSW, 2052, Australia.
⁸ Neuropsychiatric Institute, Euroa Centre, Prince of Wales Hospital, Sydney, NSW, 2052, Australia.

PMID: 32141799
DOI: 10.2217/nnm-2019-0316

Abstract

Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer's disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: 'Alzheimer's disease' AND 'nanoparticles' AND 'Magnetic Resonance Imaging.' 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.

Keywords: Alzheimer’s disease; MRI; contrast agents; diagnosis; nanoparticles.

Publication types

Research Support, Non-U.S. Gov't
Systematic Review

MeSH terms

Alzheimer Disease* / diagnostic imaging
Contrast Media*
Humans
Magnetic Resonance Imaging
Nanoparticles*

Substances

Contrast Media